

DAFTAR PUSTAKA

1. Syahrin Vidyastari Y, Emmy Riyanti D, Cahyo K. Faktor-Faktor Yang Mempengaruhi Pencapaian Target CDR (Case Detection Rate) Oleh Koordinator P2TB Dalam Penemuan Kasus Di Puskesmas Kota Semarang. Vol. 7. 2019.
2. Komalasari W, Indrawati F. Penatalaksanaan Program Pengendalian Tuberkulosis Multi Drug Resistant. 2020;
3. World Health Organization. Global Tuberculosis Report 2020. 2020;
4. Kementrian Kesehatan Republik Indonesia. Laporan Program Penanggulangan Tuberkulosis Tahun 2022. 2023.
5. BPS Provinsi Jambi. Kasus Penyakit 2022. 2023; Available from: <https://jambi.bps.go.id/indicator/30/1383/1/kasus-penyakit>
6. World Health Organization. New Treatment For Drug-Resistant Tuberculosis. : Global Tuberculosis Report 2023. 2023;
7. Kementerian Kesehatan Republik Indonesia. Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia. 2024.
8. Kementrian Kesehatan Republik Indonesia. Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat Di Indonesia. 2020.
9. Putri AF. Hubungan Efek Samping Obat Terhadap Kepatuhan Pengobatan Pasien TB MDR-DM Di RSUD Kota Tangerang Selatan Selama Pandemi COVID-19. 2021.
10. Xi Y, Zhang wei, Qiao RJ. Risk factors for multidrug-resistant tuberculosis: A worldwide systematic review and meta-analysis. 2022.
11. Restinia M, Khairani S, Manninda R. Faktor Resiko Penyebab Multidrug Resistant Tuberculosis: Sistematis Review. Pharmaceutical and Biomedical Sciences Journal (PBSJ). 2021;3:9–16.
12. Hidayathillah AP, Wahyuni CU. Model Pencegahan Tuberkulosis Resisten Obat (TB MDR) Untuk Menurunkan Angka Kejadian TB MDR.
13. Kementrian Kesehatan Republik Indonesia. Laporan Program Penanggulangan Tuberkulosis. 2021;
14. World Health Organization. Global Tuberculosis Report 2023. 2023;

15. Jang JG, Chung JH. Diagnosis and treatment of multidrug-resistant tuberculosis. 2020; Available from: <http://e-yujm.org/journal/view.php?doi=10.12701/yujm.2020.00626>
16. Indrasari AD, Fathana PB. Studi Literatur : Patogenesis Dan Diagnosis Tuberkulosis Resisten Obat. 2024;
17. Kementrian Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis. 2019;
18. Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis. jakarta; 2020.
19. Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. *New England Journal of Medicine*. 2022;387:2331–43.
20. Cohen K, Maartens G. A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis. *Expert Opin Drug Saf*. 2019;18:875–82.
21. Gaida R, Truter I, Peters CA. Adverse effects of bedaquiline in patients with extensively drug resistant tuberculosis. 2020; Available from: <http://www.sajid.co.za>
22. Borisov SE, Dheda K, Enwerem M, Leyet RR, D'Ambrosio L, Centis R, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: A multicentre study. *European Respiratory Journal*. 2017;49.
23. Salhotra VS, Sachdeva KS, Kshirsagar N, Parmar M, Ramachandran R, Padmapriyadarsini C, et al. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis. *Indian Journal of Tuberculosis*. 2020;67:29–37.
24. Huerga H, Khan U, Bastard M, Mitnick CD, Lachenal N, Khan PY, et al. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs. *Clinical Infectious Diseases*. 2022;75:1307–14.
25. Parveen P, Safura S, Heba SF, Rafi R, Begum A, Fatima N. Pretonamin: a novel therapeutic paradigm for treatment of drug resistant tuberculosis. 2020;
26. Occhineri S, Matucci T, Rindi L, Tiseo G, Falcone M, Riccardi N, et al. Pretomanid for tuberculosis treatment: an update for clinical purposes. Vol. 3, *Current Research in Pharmacology and Drug Discovery*. Elsevier B.V.; 2022.

27. Yuan Y, Li J, Chen Y, Cai Q, Xu Y, Lin L, et al. Mechanism underlying linezolid-induced peripheral neuropathy in multidrug-resistant tuberculosis. *Front Pharmacol.* 2022;13.
28. Greenberg RG, Landersdorfer CB, Rivera-Chaparro N, Harward M, Conrad T, Nakamura A, et al. Population Pharmacokinetics of Moxifloxacin in Children. *Pediatric Drugs.* 2022;24:163–73.
29. Freeman MZ, Cannizzaro DN, Naughton LF, Bove C. Fluoroquinolones-Associated Disability: It Is Not All in Your Head. *NeuroSci.* 2021;2:235–53.
30. Kementerian Kesehatan Republik Indonesia. Petunjuk Teknis Monitoring dan Manajemen Efek Samping Obat secara Aktif pada Pengobatan TBC Resistan Obat di Indonesia. 2022;
31. Rezuş C, Dan Moga V, Ouatu A, Floria M. QT interval variations and mortality risk: Is there any relationship? *Anadolu Kardiyoloji Dergisi.* 2015;15:255–8.
32. Yusra Pintaningrum Y. Fibrilasi Ventrikel: Mengenali Awitan Hingga Tatalaksana. *Unram Medical Journal.* 2021;10:494–501.
33. Heriansyah, Humaedi A, Widada N. Gambaran Ureum Dan Kreatinin Pada Pasien Gagal Ginjal Kronis Di RSUD Karawang. Program Studi Teknologi Laboratorium Medis Universitas Binawan. 2019;
34. hafiz Alwaali M, Nurmalasari Y, Fitriani D, Zulfian. Gambaran Nilai Laboratorium SGOT dan SGPT Pada Penderita Hepatitis B di RSUD Abdul Moeloek, Bandar Lampung Tahun 2021. 2023 Aug.
35. Wibawani EA, Faturahman Y, Purwanto A. Faktor-Faktor Yang Berhubungan Dengan Kejadian Dispepsia Pada Pasien Rawat Jalan Poli Penyakit Dalam Di RSUD Koja. Vol. 17, *Jurnal Kesehatan komunitas Indonesia.* 2021.
36. Frida M. Clinical Approach And Electrodiagnostic Studies Of Peripheral Neuropathy In Elderly. 2019.
37. Hunaifi I, Harahap HS, Sahidu MG, Suryani D, Indrayana Y, Dewi NMAR, et al. Edukasi Kejang, Pseudo Kejang Dan Preparasi Obat Kejang Pada Tenaga Kesehatan Rumah Sakit Universitas Mataram. *Abdi Insani.* 2021;8:302–10.
38. Angkawidjaja KMA, Soejipto. Sleep Disorders In Late-Life Depression. 2020.
39. Adnan M. Asuhan Gizi Pada Hipotiroid. *JNH (Journal of Nutrition and Health.* 2021;9:2021.

40. Sankar Mitra PhD. Arthritis: Classification, Nature & Cause-A Review [Internet]. 2013 Dec. Available from: <https://www.researchgate.net/publication/281064966>
41. Loiacono C, Palermi S, Massa B, Belviso I, Romano V, Di Gregorio A, et al. Tendinopathy: Pathophysiology, therapeutic options, and role of nutraceuticals. a narrative literature review. Vol. 55, *Medicina* (Lithuania). MDPI AG; 2019.
42. Arya NP, Pratama YAAGW. Anemia Defisiensi Besi: Diagnosis Dan Tatalaksana. 2022;2.
43. Prasetyo O, Soekanto A. The effect of arterial oxygen saturation on thrombocytopenia in pediatric patients with Tetralogy of Fallot [Internet]. Vol. 20, *HTMJ*. 2022. Available from: www.journal-medical.hangtuah.ac.id
44. Yana IGA AK, Herawati F. Efektivitas Dan Keamanan Terapi dengan Rejimen Bedaquiline dalam Terapi Multidrug-Resistant Tuberculosis (TB-MDR): Kajian Sistematis [Internet]. Vol. 7, *PHARMACEUTICAL JOURNAL OF INDONESIA* 2022. 2022 May. Available from: <http://pji.ub.ac.id>
45. Stancil SL, Mirzayev F, Abdel-Rahman SM. Profiling pretomanid as a therapeutic option for tb infection: Evidence to date. Vol. 15, *Drug Design, Development and Therapy*. Dove Medical Press Ltd; 2021. p. 2815–30.
46. Azzouz A, Preuss C V. Linezolid. In: StatPearls [Internet] National Library of Medicine [Internet]. 2024 [cited 2025 Mar 7]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK539793/>
47. Humma ZE, Patel P. Moxifloxacin. in: StatPearls [Internet] National Library of Medicine [Internet]. 2024 [cited 2025 Mar 7]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK599511/>
48. Khan MA, Ismail A, Ghafoor A, Khan N, Muzaffar N, Zafar F, et al. Experience of piloting BPaLM/BPaL for DR-TB care at selected sites in Pakistan. *IJTLD OPEN* [Internet]. 2024;1:508–15. Available from: <https://www.ingentaconnect.com/content/10.5588/ijtdopen.24.0369>
49. Labuda SM, Seaworth B, Dasgupta S, Goswami ND. Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis. Vol. 12, *The Lancet Respiratory Medicine*. Elsevier Ltd; 2024. p. e5–6.
50. Al-Qarni Bayan U, Sudarmo E, Prihanto D, Anwar M. Karakteristik Pasien Tuberkulosis Resistan Obat Di RSUD Dr. H. Chasan Boesoirie [Internet]. Vol. 4. 2022 Jun. Available from: <https://ejournal.unkhair.ac.id/index.php/kmj>

51. Mursyid A, Hanifah H, Chairani F, Nur Shobah A. Faktor Risiko Kejadian Multidrug Resistant pada Pasien Tuberkulosis Paru di RSUD Dr. Adjudarmo: Sebuah Studi Cross-Sectional. *Jurnal Ilmiah Kesehatan Delima*. 2024;7:258–63.
52. Munawwarah R, Leida I, Wahiduddin. GAMBARAN FAKTOR RISIKO PENGOBATAN PASIEN TB-MDR RS LABUANG BAJI KOTA MAKASSAR TAHUN 2013.
53. Nhamoyebonde S, Leslie A. Biological Differences Between The Sexes and Susceptibility to Tuberculosis. *Journal of Infectious Diseases*. 209.
54. Reviono, Kusnanto P, Eko V, Pakiding H, Nurwidiasih D, Pulmonologi dan Ilmu Kedokteran Respirasi B, et al. Multidrug Resistant Tuberculosis (MDR-TB): Tinjauan Epidemiologi dan Faktor Risiko Efek Samping Obat Anti Tuberkulosis. Vol. 46. 2014.
55. Sutrisna M, Elsi Rahmadani. Hubungan Usia dan Jenis Kelamin dengan TB MDR. *Sehat Rakyat: Jurnal Kesehatan Masyarakat*. 2022;1:370–6.
56. Saputra HL, Yulendasari R, Kusumaningsih D. Faktor-faktor yang berhubungan dengan Multidrug Resistant Tuberculosis (MDR-TB) pada pasien tuberkulosis paru. 2022;16:2022.
57. Arini Winarti Rinawati S. Indeks Massa Tubuh (IMT) Pasien Tuberkulosis Resisten Obat dan Kecenderungannya Terhadap Efek Samping Pengobatan. *Journal of Health Technology*. 2021;17:1–05.
58. Sulaiman D, Setiaji B, Budiati E, Rahayu D, Adhe Bianggo Naue D. Analisis Faktor Risiko Kejadian TB Paru Di Kabupaten Tulang Bawang. JPP) *Jurnal Kesehatan Poltekkes Palembang* [Internet]. 2023;18. Available from: <https://doi.org/>
59. Rasyid BS, Dewi NR, Inayati A. Implementasi Edukasi Kesehatan Tentang Penyakit TB Paru Terhadap Pengetahuan Pencegahan Penularan Penyakit TB Paru. 2024;
60. Putri Kusumandari V, Nawangsari D. Pengaruh Riwayat Pengobatan Pasien TB Terhadap Kejadian TB MDR Di RSUD Prof. DR Margono Soekarjo. Vol. 02. 2023.
61. World Health Organization. WHO consolidated guidelines on tuberculosis Module 4: Treatment Drug-resistant tuberculosis treatment 2022 update. 2022.
62. Siregar SR. Extensively Drug Resistant Tuberculosis (XDR TB). Vol. 5, *Jurnal Averrous*. 2019 Nov.

63. Nedelman JR, Salinger DH, Subramoney V, Woolson R, Wade K, Li M, et al. An Exposure-Response Perspective on the Clinical Dose of Pretomanid [Internet]. 2020. Available from: <https://doi.org/10>
64. Sangsayunh P, Sanchat T, Chuchottaworn C. The use of BPaL containing regimen in the MDR/PreXDR TB treatments in Thailand. 2024;
65. Putra ON, Purnamasari T. BPaL/BpaLM regimen: A bright future for drug-resistant tuberculosis. *Asian Pac J Trop Med*. 2024;17:335–7.